Well Referenced

Tag: tau aggregation inhibitor

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease

This 2019 study analyzed data from two Phase III trials involving 1,162 patients with mild to moderate Alzheimer’s disease (AD) to assess the relationship between hydromethylthionine (LMTM) plasma concentration and clinical outcomes. Findings revealed that even at a low dose of 8 mg/day, patients with higher plasma levels experienced significant

Read More »
June 26, 2025 No Comments

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

This Phase III clinical trial evaluated the efficacy of LMTM, a tau aggregation inhibitor, as monotherapy in patients with mild Alzheimer’s disease (AD). The study involved 800 participants randomized to receive either 100 mg or 4 mg of LMTM twice daily. Prior to unblinding, the analysis plan was revised to

Read More »
June 26, 2025 No Comments